The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

A new poll from The Associated Press-NORC Center for Public Affairs Research shows about half of U.S. adults believe it is a good thing for adults to use weight-loss drugs like Ozempic, Wegovy and ...

CBS News Miami investigates the financial hurdles surrounding these medications and explores alternatives that may offer a ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The glucagon-like peptide-1 receptor agonists improve glycemia and induce a modest weight loss, but there are doubts over their long-term safety. New drugs such as lorcaserin and phentermine ...

Scientists discovered that participants who concentrated on dietary changes maintained an average weight loss of 17 pounds after one year, compared to just 3 pounds for those who relied primarily ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

Lizzo is feeling "Good as Hell" as she celebrates a major milestone in her weight loss journey. The "About Damn Time" singer, 36, shared Saturday on Instagram that she has "reached my weight ...

which could have improved the average weight loss magnitude for amycretin by 4.5% to 5.0%. Furthermore, the company did not say how many patients discontinued the study drug in the clinical trial.

In 2023, the American Academy of Pediatrics published a clinical practice guideline recommending weight-loss medications, including glucagon-like peptide-1 (GLP-1) receptor agonists, as a supplement ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.